Abstract
One of the countries most adversely affected by the COVID-19 outbreak was Peru. Worldwide scientific knowledge creation has significantly grown because of this pandemic. This systematic study aims to examine several facets of Peru’s experimental scientific production concerning COVID-19. Between December 2019 and June 2022, searches were made in the PubMed database for experimental scientific articles created in Peruvian institutions. The systematic review resulted in nine studies that meet the requirements. Data were extracted and analyzed on the type of biomedical research, the study’s applicability, the thematic area and specific thematic, journal impact factor and quartile, funding, grants, and institution of affiliation for the first and correspondence authors. The results revealed that Peru needs to promote policies to boost research funding and the number of researchers to produce information that will be useful for managing diseases in the future. Yet, despite the funding provided by national organizations like National Council for Science, Technology, and Technological Innovation (CONCYTEC), there were few publications and little international collaboration. The studies that have been published focus mostly on applied research in the areas of diagnostics, sanitary products, and treatment and transmission, and they have great visibility because they are indexed in Q1 journals. This thorough study revealed Peru’s inadequate reaction to COVID-19 regarding experimental scientific research. Peruvian authorities should think about supporting the required policies to boost the number of researchers and financial aid to produce information that may be utilized to manage potential new diseases in the future.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by Universidad Catolica de Santa Maria (grants 27574-R-2020, and 28048-R-2021).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- CONCYTEC
- National Council for Science, Technology, and Technological Innovation
- COVID-19
- Coronavirus disease
- FARVET SAC
- Farmacológicos Veterinarios SAC
- FONDECYT
- National Funding for Scientific and Technological Development
- INPLASY
- International Platform of Registered Systematic Review and Meta-analysis Protocols
- INS
- National Health Institute
- MeSH
- Medical Subject Headings
- NML
- National Library of Medicine
- NCBI
- National Center for Biotechnology Information
- PMC
- PubMed Central
- PMID
- PubMed Identifier
- PRISMA
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- RENACYT
- National Scientific, Technological and Technological Innovation Registry
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
